The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

Objectives: To study the long-term CD4 cell responses to highly active antiretroviral therapy (HAART) in treatment-naive patients whose viral loads remained below 500 copies/ml for prolonged periods. Design: A total of 237 patients whose viral loads remained below 500 copies/ml for one year or more. Median follow-up was 1.9 years. Methods: CD4 cell counts were analysed to investigate long-term immunological response using mixed-effects models with the slope allowed to change after 1, 12 and 24 months of HAART. Results: The median baseline CD4 cell count was 175 cells/mm3. After an initial rapid increase in the first month after HAART (97.2 cells/mm3 a month), increases in CD4 cell counts continued less rapidly (11.6 cells/mm3 a month). This increase slowed by 2.4 cells/mm3 a month after one year. CD4 cell counts continued increasing after 2 years, but the rate of increase again slowed (estimated slope at 2 years 5.4 cells/mm3 a month; decrease in slope from year 2 compared with years 1–2 3.7 cell/mm3 a month). A total of 198 out of 211 patients (94%) with measurements at baseline and one year experienced an increase in CD4 cell counts in this interval; 81 and 67% had an increasing slope between 1 and 2 and 2 and 3 years, respectively. By the end of follow-up, CD4 cell counts had increased by 319 cells/mm3, and were more than 500 cells/mm3 in 40% of patients. Conclusion: Although the rate of immune recovery slowed after 2 years, CD4 cell counts rose in most and began to return to levels seen in HIV-negative individuals.

[1]  D. Richman,et al.  Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.

[2]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[3]  J. Margolick,et al.  Increase and Plateau of CD4 T‐Cell Counts in the 3½ Years After Initiation of Potent Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[4]  D. Cooper,et al.  The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy , 2002, AIDS.

[5]  C. Sabin,et al.  CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. , 2002, AIDS.

[6]  M. Lederman,et al.  Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. , 2000, The Journal of infectious diseases.

[7]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[8]  D. Cooper,et al.  Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection , 2000, AIDS.

[9]  R. Weber,et al.  Long‐Term Evaluation of T‐Cell Subset Changes After Effective Combination Antiretroviral Therapy During Asymptomatic HIV‐Infection , 2001, Journal of acquired immune deficiency syndromes.

[10]  A. Phillips,et al.  Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. , 1996, Genitourinary medicine.

[11]  B. Gazzard,et al.  The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. , 2001, The Journal of infection.

[12]  M. Lederman,et al.  Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. , 1999, The Journal of infectious diseases.

[13]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[14]  A. Badley,et al.  Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. , 2001, The Journal of infectious diseases.

[15]  A. Phillips,et al.  The cumulative risk of AIDS as the CD4 lymphocyte count declines. , 1992, Journal of acquired immune deficiency syndromes.

[16]  R. Siliciano,et al.  Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. , 2001, The Journal of infectious diseases.

[17]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[18]  N. Foudraine,et al.  Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. , 1999, The Journal of infectious diseases.

[19]  V. Calvez,et al.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease , 1998, The Lancet.

[20]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[21]  E. Sandström,et al.  Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. , 2001, AIDS research and human retroviruses.

[22]  M. Lederman,et al.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. , 1998, The Journal of infectious diseases.

[23]  A. Phillips,et al.  Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophilic cohort. , 1989, AIDS.

[24]  Richard Hodes,et al.  Visiting Solomon: AIDS in Ethiopia. , 2002, AIDS.

[25]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[26]  S. Yerly,et al.  Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy , 2000, AIDS.

[27]  C. Sabin,et al.  Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV‐1 diagnosis , 1992, Clinical and experimental immunology.

[28]  D. Cooper,et al.  Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy , 2000, AIDS.

[29]  H. Furrer,et al.  HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. , 1999, AIDS.

[30]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[31]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[32]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.